This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.
This is a Phase 2, proof-of-concept, multi-center, randomized, double blind, placebo-controlled study designed to evaluate the efficacy, safety and tolerability of RAP-219 in adult participants experiencing mania associated with bipolar I disorder. This is a 3-week inpatient clinical trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
224
Pillar Clinical Research - Little Rock
Young Mania Rating Scale (YMRS)
The YMRS is a clinician administered scale that consists of 11 items used to assess the severity of manic symptoms (total scores range from 0 to 60). The higher the YMRS score, the more severe the subject's symptoms of mania.
Time frame: Baseline to End of Treatment at Week 3
Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness Mania score
The CGI-BP Severity of Illness Mania score is a clinician-rated scale used to assess the severity of manic symptoms, depression and overall illness severity in individuals with bipolar disorder. The mania score ranges from 1 (not ill) to 7 (very severely ill), with higher scores indicating greater severity of manic symptoms.
Time frame: Baseline to end of Treatment at Week 3
Treatment Emergent Adverse Events (TEAEs)
Incidence and severity of treatment-emergent adverse events (TEAEs).
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Heart Rate
Change in Heart Rate (BPM)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Respiratory Rate
Change in Respiratory Rate (breaths per minute)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Body Temperature
Change in body temperature
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Blood Pressure
Change in blood pressure (Hg mm)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Little Rock, Arkansas, United States
Woodland International Research Group
Little Rock, Arkansas, United States
RECRUITINGWoodland Research Northwest
Rogers, Arkansas, United States
RECRUITINGInland Psychiatric Medical Group - Chino
Chino, California, United States
RECRUITINGSynergy Clinical Research Center - San Diego
Lemon Grove, California, United States
RECRUITINGCollaborative Neuroscience Research - Los Alamitos
Los Alamitos, California, United States
RECRUITINGNRC Research Institute - Orange
Orange, California, United States
RECRUITINGCNRI - San Diego, LLC
San Diego, California, United States
RECRUITINGNeuroBehavioral Hospitals of the Palm Beaches - South
Boynton Beach, Florida, United States
RECRUITINGUnited Research Institute
Hialeah, Florida, United States
RECRUITING...and 12 more locations
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Laboratory Analytes
Change in laboratory analytes (absolute value)
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Electrocardiogram (ECG) QTc interval
Changes in electrocardiogram (ECGs); QTc prolongation
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Electrocardiogram (ECG) abnormal findings
Shift table of normal to abnormal ECG findings
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose
Suicidality
Incidence of suicidality using the Columbia-Suicide Severity Rating Scale (C-SSRS).
Time frame: Baseline to end of Study Period 8 Weeks after date of last dose